Zhejiang Orient Gene Biotech Co Ltd (688298) — Working Capital to Net Assets Ratio
Zhejiang Orient Gene Biotech Co Ltd (688298) has a Working Capital to Net Assets ratio of 39.7% as of September 2025. Working capital of CN¥2.58 Billion (current assets of CN¥3.37 Billion minus current liabilities of CN¥786.58 Million) is measured against net assets of CN¥6.49 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See 688298 days of operational coverage to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Zhejiang Orient Gene Biotech Co Ltd Working Capital to Net Assets (2016–2024)
This chart shows how Zhejiang Orient Gene Biotech Co Ltd's Working Capital to Net Assets ratio has evolved across 9 annual periods from 2016 to 2024. As of September 2025, the ratio stands at 39.7%, reflecting working capital of CN¥2.58 Billion against net assets of CN¥6.49 Billion CNY. For the complete balance sheet picture, see Zhejiang Orient Gene Biotech Co Ltd total assets.
Annual Working Capital to Net Assets for Zhejiang Orient Gene Biotech Co Ltd (2016–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Zhejiang Orient Gene Biotech Co Ltd from 2016 to 2024, covering 9 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check 688298 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 40.9% | CN¥2.77 Billion | CN¥6.79 Billion | CN¥3.98 Billion | CN¥1.20 Billion | ▼ -22.9 pp |
| 2023 | 63.7% | CN¥4.81 Billion | CN¥7.55 Billion | CN¥5.90 Billion | CN¥1.09 Billion | ▼ -14.0 pp |
| 2022 | 77.7% | CN¥6.47 Billion | CN¥8.32 Billion | CN¥8.75 Billion | CN¥2.28 Billion | ▼ -10.4 pp |
| 2021 | 88.1% | CN¥6.07 Billion | CN¥6.89 Billion | CN¥8.13 Billion | CN¥2.06 Billion | ▼ -1.9 pp |
| 2020 | 90.0% | CN¥2.21 Billion | CN¥2.45 Billion | CN¥3.32 Billion | CN¥1.11 Billion | ▲ +23.8 pp |
| 2019 | 66.2% | CN¥168.17 Million | CN¥254.13 Million | CN¥259.69 Million | CN¥91.52 Million | ▲ +7.3 pp |
| 2018 | 58.9% | CN¥122.46 Million | CN¥208.03 Million | CN¥243.72 Million | CN¥121.26 Million | ▲ +13.1 pp |
| 2017 | 45.8% | CN¥63.23 Million | CN¥138.12 Million | CN¥179.73 Million | CN¥116.50 Million | ▲ +13.6 pp |
| 2016 | 32.2% | CN¥31.77 Million | CN¥98.72 Million | CN¥168.85 Million | CN¥137.08 Million | — |